Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Suk-Young Yoo"'
Autor:
Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for cur
Externí odkaz:
https://doaj.org/article/85c0508e98f2481db714933c819add16
Autor:
Dirk Schadendorf, Chieh-I Chen, Zhen Chen, Israel Lowy, Elizabeth Stankevich, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Anne Lynn S Chang, Emmanuel Okoye, Jocelyn Booth, Siyu Li, Matthew G Fury, Alexander Guminski, Medha Sasane, Alesha A Thai, Suk-Young Yoo, Vera Mastey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Metho
Externí odkaz:
https://doaj.org/article/909409bad2c44f6ca8b681b154002319